TELESIS BIO INC (TBIO)
US1920031010 - Common Stock
TBIO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. While TBIO seems to be doing ok healthwise, there are quite some concerns on its profitability. TBIO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TBIO has reported negative net income.
In the past year TBIO has reported a negative cash flow from operations.
In the past 5 years TBIO always reported negative net income.
TBIO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -69.63%, TBIO is doing worse than 93.10% of the companies in the same industry.
TBIO has a worse Return On Equity (-165.98%) than 86.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.63% | ||
| ROE | -165.98% | ||
| ROIC | N/A |
ROA(3y)-54.22%
ROA(5y)-50.2%
ROE(3y)-104.3%
ROE(5y)-94.55%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 61.62%, TBIO belongs to the top of the industry, outperforming 87.93% of the companies in the same industry.
TBIO's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for TBIO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.75%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TBIO has been increased compared to 1 year ago.
The debt/assets ratio for TBIO has been reduced compared to a year ago.
2.2 Solvency
TBIO has an Altman-Z score of -2.17. This is a bad value and indicates that TBIO is not financially healthy and even has some risk of bankruptcy.
TBIO has a Altman-Z score of -2.17. This is amonst the worse of the industry: TBIO underperforms 82.76% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that TBIO is not too dependend on debt financing.
TBIO has a Debt to Equity ratio (0.18) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.17 |
ROIC/WACCN/A
WACC12.73%
2.3 Liquidity
A Current Ratio of 3.71 indicates that TBIO has no problem at all paying its short term obligations.
The Current ratio of TBIO (3.71) is better than 62.07% of its industry peers.
TBIO has a Quick Ratio of 3.22. This indicates that TBIO is financially healthy and has no problem in meeting its short term obligations.
TBIO has a better Quick ratio (3.22) than 63.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.71 | ||
| Quick Ratio | 3.22 |
3. Growth
3.1 Past
The earnings per share for TBIO have decreased strongly by -593.94% in the last year.
TBIO shows a small growth in Revenue. In the last year, the Revenue has grown by 0.25%.
The Revenue has been growing by 61.10% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-593.94%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2QN/A
Revenue 1Y (TTM)0.25%
Revenue growth 3Y61.1%
Revenue growth 5YN/A
Revenue growth Q2Q-45.54%
3.2 Future
Based on estimates for the next years, TBIO will show a very strong growth in Earnings Per Share. The EPS will grow by 39.58% on average per year.
TBIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.04% yearly.
EPS Next Y93.05%
EPS Next 2Y39.58%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year29.09%
Revenue Next 2Y30.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TBIO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TBIO's earnings are expected to grow with 39.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.58%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for TBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TELESIS BIO INC
NASDAQ:TBIO (5/17/2024, 3:30:01 PM)
4.5
+0.15 (+3.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap135.45M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.63% | ||
| ROE | -165.98% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.62% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.71 | ||
| Quick Ratio | 3.22 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-593.94%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y93.05%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)0.25%
Revenue growth 3Y61.1%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y